Microflora-improving agent

A flora-improving agent with defined compounds and bases effectively inhibits pathogenic bacteria while preserving non-pathogenic bacteria, maintaining bacterial balance and improving mucous membranes, skin, and nail health.

CN119072307APending Publication Date: 2024-12-03SANYO CHEM IND LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035075.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-27
Filing Date
2023-04-20
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing flora-improving agents, such as those described in Patent Document 1, inhibit both pathogenic and non-pathogenic bacteria, disrupting the balance of the bacterial flora and are difficult to maintain over time.

Method used

A flora-improving agent containing specific compounds and bases with defined mass ratios and HLB values, selectively inhibiting pathogenic bacteria while maintaining non-pathogenic bacteria, utilizing compounds like those with hydroxyl and oxyacid groups, heterocyclic compounds, and ketones with linear β-diketone structures, and a base with an HLB value of 7 or more.

Benefits of technology

The agent effectively inhibits pathogenic bacteria, maintains non-pathogenic bacteria, and sustains flora balance by selectively targeting quorum sensing mechanisms, thereby improving mucous membranes, skin, and nail health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005091879710000041
    Figure BDA0005091879710000041
  • Figure BDA0005091879710000051
    Figure BDA0005091879710000051
  • Figure BDA0005091879710000052
    Figure BDA0005091879710000052
Patent Text Reader

Abstract

The purpose of the present invention is to provide a flora-improving agent for improving the flora of mucous membranes, skin and / or nails, the flora-improving agent exhibiting a high pathogenic bacterium-inhibiting effect while maintaining non-pathogenic resident bacteria and being capable of continuously improving the flora balance. A flora-improving agent for improving the flora of mucous membranes, skin and / or nails according to the present invention contains a substance (X) and a base (Y) containing a non-volatile component, the substance (X) is at least one substance selected from the group consisting of a compound (X1) having two or more hydroxyl groups included in an oxyacid group and a salt thereof, a compound (X2) having one hydroxyl group included in an oxyacid group and a salt thereof, a heterocyclic compound (X3) not having an oxyacid group and a salt thereof, and a ketone (X4) not having an oxyacid group, the non-volatile component has an HLB value of 7 or more, and the flora-improving agent satisfies the following conditions (i)-(ii. (i) The mixed consistency of the flora-improving agent as measured in accordance with JIS K 2220 is 100 to 400. (ii) The viscosity of the flora-improving agent at 37 DEG C as measured by a cone-plate rotational viscometer is 1-4, 000 Pa * s.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a flora improving agent. Background Art

[0002] Various bacteria coexist in the human body [mucous membranes (inside the mouth, etc.), skin, nails, etc.], forming a bacterial group called a flora. In this flora, so-called non-pathogenic resident bacteria and bacteria showing pathogenicity coexist.

[0003] Normally, the microbial flora is in a so-called healthy state in which a balance is maintained, and diseases caused by pathogenic bacteria are suppressed.

[0004] However, when the balance of the flora is disrupted due to diet, antibiotic intake, stress, aging, poor cleaning, etc., pathogenic bacteria and opportunistic infection bacteria will increase and cause diseases. Therefore, for disease control, it is important not only to suppress pathogenic bacteria, but also to maintain a healthy balance between them and non-pathogenic resident bacteria.

[0005] In addition, as described in Patent Document 1, there is known a technique related to a pathogenic factor production inhibitor that exhibits a function of acting on specific harmful bacteria.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: Japanese Patent No. 5716173 Summary of the invention

[0009] Problems to be solved by the invention

[0010] However, the results of the study show that when the pathogenic factor production inhibitor described in Patent Document 1 is used directly, it will not only inhibit the action of pathogenic bacteria, but also have many adverse effects on non-pathogenic resident bacteria, and it is difficult to continuously inhibit the action of pathogenic bacteria at the site of use. In order to keep the balance of the bacterial flora in a healthy state, improved means are needed.

[0011] Therefore, an object of the present invention is to provide a flora-improving agent for improving the flora of mucous membranes, skin and / or nails, which exhibits a high inhibitory effect on pathogenic bacteria while maintaining non-pathogenic resident bacteria and can continuously improve the flora balance.

[0012] Means for solving problems

[0013] The inventors of the present invention have conducted intensive research to solve the above-mentioned problems, and have thus achieved the present invention. That is, the present invention relates to a flora improving agent for improving the flora of mucous membranes, skin and / or nails, which contains a substance (X) and a base (Y) containing a non-volatile component, wherein the substance (X) is at least one selected from the group consisting of a compound (X1) having two or more hydroxyl groups contained in an oxyacid group and a salt thereof, a compound (X2) having one hydroxyl group contained in an oxyacid group and a salt thereof, a heterocyclic compound (X3) having no oxyacid group and a salt thereof, and a ketone (X4) having no oxyacid group, wherein:

[0014] The total mass ratio of the oxyacid groups, hydroxyl groups not contained in the oxyacid groups, carbonyl groups not contained in the oxyacid groups, carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton of the compound (X1) is 45% by mass or more, based on the molecular weight of the compound (X1),

[0015] The compound (X2) contains an atom having an unshared electron pair (excluding atoms contained in an oxoacid group, and atoms contained in an amino group that does not constitute an imidazole skeleton and an amino group that does not constitute a pyridine skeleton).

[0016] The total mass ratio of the oxyacid groups, hydroxyl groups not contained in the oxyacid groups, carbonyl groups not contained in the oxyacid groups, carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton of the compound (X2) is 55% by mass or more, based on the molecular weight of the compound (X2);

[0017] The heterocyclic compound (X3) has an imidazole skeleton or a pyridine skeleton, and a hydroxyl group and / or a carbonyl group, or has two or more skeletons selected from imidazole skeletons and pyridine skeletons,

[0018] The above ketone (X4) has a linear β-diketone structure,

[0019] The molecular weight of substance (X) is 550 or less,

[0020] The HLB value of the non-volatile component is 7 or more,

[0021] The microflora improving agent meets the following conditions (i) to (ii):

[0022] (i) The above-mentioned flora improving agent has a mixing consistency of 100 to 400 as measured in accordance with JIS K 2220.

[0023] (ii) The above-mentioned bacterial flora improving agent has a viscosity at 37° C. of 1 to 4,000 Pa·s as measured by a cone-plate rotational viscometer.

[0024] Effects of the Invention

[0025] According to the present invention, there can be provided a flora improving agent for improving the flora of mucous membranes, skin and / or nails, which exhibits a high inhibitory effect on pathogenic bacteria while maintaining non-pathogenic resident bacteria and can continuously improve the flora balance. DETAILED DESCRIPTION

[0026] The flora improving agent for improving the flora of mucous membranes, skin and / or nails of the present invention (hereinafter also referred to as "the flora improving agent of the present invention") contains a substance (X) and a base (Y) containing a non-volatile component, wherein the substance (X) is at least one selected from the group consisting of a compound having two or more hydroxyl groups contained in an oxyacid group (X1) and a salt thereof, a compound having one hydroxyl group contained in an oxyacid group (X2) and a salt thereof, a heterocyclic compound not having an oxyacid group (X3) and a salt thereof, and a ketone not having an oxyacid group (X4).

[0027] The flora improving agent of the present invention exhibits the effect of maintaining non-pathogenic resident bacteria while exhibiting a high pathogenic bacteria inhibitory effect, thereby improving the flora balance.

[0028] It should be noted that the above-mentioned “high inhibitory effect on pathogenic bacteria” refers to at least any one of killing harmful bacteria, inactivating harmful bacteria to inhibit their proliferation, and inhibiting the production of toxic substances (pathogenic factors) of harmful bacteria.

[0029] In the present specification, "pathogenic bacteria" refers to bacteria, fungi, etc. that are highly pathogenic and cause various infectious diseases by proliferation. Specifically, Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella intermedia, Trichophyton rubrum, Trichophyton mentagrophytes, Candida albicans, Candida glabrata, etc. can be mentioned.

[0030] In addition, "non-pathogenic resident bacteria" refers to resident bacteria that inhibit the growth of the above-mentioned pathogenic bacteria and have a function of maintaining health, and specific examples thereof include Staphylococcus epidermidis and Streptococcus salivarius.

[0031] It should be noted that, among the above-mentioned pathogenic bacteria, Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia are known to be pathogenic bacteria that can be produced in the oral cavity.

[0032] Among the above-mentioned pathogenic bacteria, Trichophyton rubrum, Trichophyton mentagrophytes, Staphylococcus aureus, Candida albicans, and Candida glabrata are known to be pathogenic bacteria that can be produced on the skin and nails.

[0033] It should be noted that, among the above-mentioned non-pathogenic bacteria, Streptococcus salivarius is known to be a resident bacterium existing in the oral cavity.

[0034] Among the above-mentioned non-pathogenic bacteria, Staphylococcus epidermidis is known to be a resident bacterium existing in the skin and nails.

[0035] The flora improving agent of the present invention can selectively inhibit the quorum sensing mechanism of pathogenic bacteria (ie, the mechanism of producing autoinducers), and has a high inhibitory effect on pathogenic bacteria while maintaining non-pathogenic resident bacteria.

[0036] [Matter (X)]

[0037] The bacterial flora improving agent of the present invention contains a substance (X).

[0038] The substance (X) is at least one selected from the group consisting of a compound (X1) having two or more hydroxyl groups contained in an oxyacid group and a salt thereof, a compound (X2) having one hydroxyl group contained in an oxyacid group and a salt thereof, a heterocyclic compound (X3) not having an oxyacid group and a salt thereof, and a ketone (X4) not having an oxyacid group.

[0039] As the substance (X), two or more kinds of the compound (X1), the compound (X2), the heterocyclic compound (X3) and the ketone (X4) may be used respectively. Alternatively, two or more kinds of the salt of the compound (X1), the salt of the compound (X2) and the salt of the compound (X3) may be used respectively.

[0040] The compound (X1) has two or more hydroxyl groups contained in the oxyacid group. The compound (X1) may have two or more oxyacid groups.

[0041] In the present application, "oxyacid group" refers to a group having a structure in which a hydroxyl group (-OH) and an oxo group (=O) are bonded to a central atom (carbon atom, phosphorus atom, sulfur atom, tungsten atom, etc.). Two or more hydroxyl groups and oxo groups may be contained in one oxyacid group.

[0042] For example, triphosphoric acid has two types of oxyacid groups: -P(=O)(OH)2 at both ends of the molecule and -P(=O)(OH)- in the center. The oxyacid groups at both ends include two hydroxyl groups.

[0043] [Chemistry 1]

[0044]

[0045] From the aspect of the effect of the flora improver, based on the molecular weight of compound (X1), the total mass ratio of the oxyacid groups, hydroxyl groups not contained in the oxyacid groups, carbonyl groups (C=O) not contained in the oxyacid groups, carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton possessed by compound (X1) is 45% by mass or more, preferably 55% by mass or more. When the flora improver contains two or more compounds as compound (X1), each compound satisfies this condition. In the present application, the mass of the oxyacid group is the total mass of the central atom, the oxo group and the hydroxyl group.

[0046] For example, malic acid with a molecular weight of 134.1

[0047] [Chemistry 2]

[0048]

[0049] In the case of , there are two carboxyl groups (formula weight 45.0) as oxygen-containing acid groups and one hydroxyl group (formula weight 17.0) not included in the oxygen-containing acid group. Therefore, based on the molecular weight of malic acid, the total mass ratio of these groups is

[0050] [(45.0×2+17.0×1) / 134.1]×100=80 (mass %).

[0051] Compound (X1) has an oxo acid group as an essential group, but a hydroxyl group not included in the oxo acid group, a carbonyl group not included in the oxo acid group, an imidazole skeleton and a pyridine skeleton are not essential but optionally included.

[0052] In this application, "imidazole skeleton" refers to

[0053] [Chemistry 3]

[0054]

[0055] The structure represented by (R is a hydrogen atom or a group that can be bonded to imidazole).

[0056] In addition, the "pyridine skeleton" refers to

[0057] [Chemistry 4]

[0058]

[0059] The structure represented.

[0060] These structures may be contained in fused rings.

[0061] In addition, from the perspective of further improving the effect of the microbial flora improving agent, the total mass ratio of the oxyacid groups, the hydroxyl groups not contained in the oxyacid groups and the carbonyl groups not contained in the oxyacid groups possessed by the above-mentioned compound (X1) is preferably 45% by mass or more, based on the molecular weight of the compound (X1).

[0062] Examples of compound (X1) include polyphosphoric acid, tungstic acid (H2WO4), ethylenediaminetetraacetic acid, glutamic acid, iminodiacetic acid, malic acid, citric acid, tartaric acid, adenosine triphosphate, guanosine triphosphate, etc. It should be noted that, in the present application, as shown in the following chemical formula (1), tungstic acid is regarded as a compound having two hydroxyl groups contained in an oxoacid group, which is included in compound (X1).

[0063] [Chemistry 5]

[0064]

[0065] From the viewpoint of the effect of the microflora improving agent, the compound (X1) preferably has no "-NH2" group.

[0066] When compound (X1) is a hydroxycarboxylic acid, from the perspective of the effect of the flora improving agent, the ratio of the number of moles of hydroxyl groups possessed by the hydroxycarboxylic acid to the number of moles of carboxyl groups (-COOH) (number of moles of -OH / number of moles of -COOH) is preferably 1 / 3 or more, more preferably 1 / 2 or more.

[0067] The salt of compound (X1) is not particularly limited, and examples thereof include inorganic acid salts such as hydrochlorides, sulfates, nitrates, and phosphates; organic acid salts such as acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates, and propionates; alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; salts with organic bases such as triethylamine, triethanolamine, and pyridine; amino acid salts with basic amino acids or acidic amino acids such as arginine and glutamic acid; and the like. Among these, sodium salts and potassium salts are preferred.

[0068] Compound (X2) contains atoms having an unshared electron pair (however, excluding atoms included in an oxo acid group, and atoms included in an amino group that does not constitute an imidazole skeleton and an amino group that does not constitute a pyridine skeleton).

[0069] Preferred examples of the atom having an unshared electron pair include an oxygen atom contained in a carbonyl group, an oxygen atom contained in a hydroxyl group (excluding an oxygen atom contained in an oxyacid group), a nitrogen atom contained in an imidazole skeleton, and a nitrogen atom contained in a pyridine skeleton.

[0070] In addition, from the aspect of the effect of the flora improving agent, based on the molecular weight of the compound (X2), the total mass ratio of the oxyacid group, the hydroxyl group not contained in the oxyacid group, the carbonyl group not contained in the oxyacid group, the carbon atom contained in the imidazole skeleton and the pyridine skeleton, and the nitrogen atom contained in the imidazole skeleton and the pyridine skeleton possessed by the compound (X2) is 55% by mass or more. When the flora improving agent contains two or more compounds as the compound (X2), each compound satisfies this condition.

[0071] Compound (X2) has an oxoacid group as an essential group, and optionally has a hydroxyl group not included in the oxoacid group, a carbonyl group not included in the oxoacid group, an imidazole skeleton, and a pyridine skeleton.

[0072] Examples of the compound (X2) include a compound (X21) not having an amino group and a compound (X22) having an amino group.

[0073] Examples of the compound (X21) not having an amino group include hydroxycarboxylic acids (gluconic acid, glucuronic acid, etc.), keto acids (levulinic acid, etc.), and the like.

[0074] Examples of the compound (X22) having an amino group include glycylglycine and histidine.

[0075] Examples of the salt of compound (X2) include the same salts as described above as the salt of compound (X1), and preferred examples are also the same.

[0076] The heterocyclic compound (X3) has an imidazole skeleton or a pyridine skeleton, and a hydroxyl group and / or a carbonyl group, or has two or more skeletons selected from an imidazole skeleton and a pyridine skeleton.

[0077] Examples of the heterocyclic compound (X3) include 8-hydroxyquinoline (a compound having one pyridine skeleton and a hydroxyl group) and phenanthroline (a compound having two pyridine skeletons).

[0078] From the aspect of the effect of the flora improving agent, the total mass ratio of the carbon atoms contained in the imidazole skeleton and the pyridine skeleton, the nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton, the hydroxyl group, and the carbonyl group of the heterocyclic compound (X3) is preferably 50% by mass or more, based on the molecular weight of the heterocyclic compound (X3). When the flora improving agent contains two or more compounds as the heterocyclic compound (X3), it is preferred that each compound satisfies this condition.

[0079] Examples of the salt of the heterocyclic compound (X3) include the same salts as described above as the salt of the compound (X1).

[0080] Ketone (X4) has a linear β-diketone structure.

[0081] The ketone (X4) may be a salt having a counter ion.

[0082] Examples of the ketone (X4) include benzoylacetone and acetylacetone.

[0083] From the perspective of the effect of the microflora improving agent, the total mass ratio of the carbonyl groups possessed by the ketone (X4) is preferably 30% by mass or more, based on the molecular weight of the ketone (X4) [wherein, when the ketone (X4) is a salt having a counter ion, it refers to the mass of the ion having a linear β-diketone structure other than the counter ion]. When the microflora improving agent contains two or more compounds as ketones (X4), it is preferred that each compound satisfies this condition.

[0084] As substance (X), from the perspective of safety, it is preferably at least one selected from the group consisting of levulinic acid and its salts, tungstic acid and its salts, benzoylacetone, polyphosphoric acid and its salts, and acetylacetone, more preferably polyphosphoric acid (the number of repetitions of the phosphoric acid unit is preferably 2 to 5, more preferably 3 to 5) and its salts, and particularly preferably pentasodium triphosphate.

[0085] From the viewpoint of the effect of the microflora improving agent, the molecular weight of the substance (X) is 550 or less. When the microflora improving agent contains two or more compounds as the substance (X), the molecular weight of each molecule is 550 or less.

[0086] The amount of magnesium captured by the substance (X) when measured by an ion electrode method is preferably 1 g or more per 100 g of the substance (X).

[0087] In addition, when the substance (X) is a hydrate, it means the weight excluding hydration water per 100 g.

[0088] The above-mentioned measurement based on the ion electrode method was carried out using 2 mM of the substance (X) in a 1 mM MgCl2 aqueous solution at 20°C and pH 7.

[0089] [Base (Y)]

[0090] The microflora improving agent of the present invention contains not only the substance (X) but also a base (Y) containing a non-volatile component. It should be noted that the substance (X) is not a component contained in the base (Y).

[0091] The HLB value of the nonvolatile component in the base (Y) is 7 or more. When the HLB value of the nonvolatile component is less than 7, the spreadability of the flora improving agent when applied to the affected area is deteriorated. From the perspective of spreadability, the HLB value of the nonvolatile component is preferably 7 to 60. Components with an HLB value of 7 or more contained in the flora improving agent are regarded as nonvolatile components in the base (Y).

[0092] The HLB value is an index showing the balance between hydrophilicity and lipophilicity, and is known to be a calculated value obtained by the Oda method described in, for example, "Introduction to Surfactants" [published by Sanyo Chemical Industries, Ltd. in 2007, written by Takehiko Fujimoto], page 212, rather than a calculated value obtained by the Griffin method.

[0093] The HLB value of the compound as a nonvolatile component can be calculated by the following formula based on the ratio of the organic value to the inorganic value of the compound.

[0094] HLB=10×Inorganic value / Organic value

[0095] Regarding the organic and inorganic values ​​used to derive HLB, as the organic value, 20 is defined per carbon atom, and as the inorganic value, the value in the table described in the above-mentioned "Introduction to Surfactants" on page 213 (the "numerical value" in the inorganic group, or the "inorganic" numerical value in the organic and inorganic group) is used for calculation. As a calculation example, the following can be cited:

[0096] -CH3 group: organic value 20, inorganic value 0,

[0097] -CH2- group: organic value 20, inorganic value 0,

[0098] =CH2 group: organic value 20, inorganic value 1,

[0099] =CH- group: organic value 10, inorganic value 1,

[0100] Benzene ring: organic value 120, inorganic value 15,

[0101] -O- group: inorganic value 20,

[0102] -COO-: organic value 20, inorganic value 60,

[0103] -OH group: Inorganic value 100,

[0104] -COOH group: organic value 20, inorganic value 150.

[0105] In addition, in the calculation of the HLB value in the present invention, the organic value and the inorganic value shown below were used for the following configurations.

[0106] COO - M + : Organic value 20, inorganic value 400 (It should be noted that "M + ” is “COO - " counter ion, representing a metal cation or an ammonium cation)

[0107] Si atom: organic value 0, inorganic value 0

[0108] In addition, when the non-volatile component is composed of a plurality of components, a value obtained by weighted average based on the weight ratio of each component is used as the HLB value of the non-volatile component.

[0109] In addition, the "non-volatile component" in the present invention refers to the residue after the sample is heated and dried in a circulating air dryer at 130° C. for 45 minutes in a glass petri dish without covering it.

[0110] From the viewpoint of the effect of the flora improving agent, the content (weight ratio) of the nonvolatile component is preferably 0.1 to 80% by weight, more preferably 1 to 70% by weight, based on the weight of the flora improving agent.

[0111] From the viewpoint of the effect of the flora improving agent, the content (weight ratio) of the nonvolatile component is preferably 30 to 6,000% by weight, more preferably 50 to 5,000% by weight, based on the weight of the substance (X).

[0112] As the non-volatile component in the base agent (Y), a polymer having a weight-average molecular weight of 10,000 to 3,000,000 is preferred. In addition, as the compound contained in the polymer having a weight-average molecular weight of 10,000 to 3,000,000, a molecular weight of 500 or more is preferred. Among the polymers contained in the flora improver, those having a weight-average molecular weight of 10,000 to 3,000,000 and an HLB value of 7 or more are regarded as the non-volatile components in the base agent (Y).

[0113] It should be noted that the weight-average molecular weight in this specification can be measured using a gel permeation chromatograph (GPC) under the following conditions and the like.

[0114] <GPC measurement conditions>

[0115] [1] Apparatus: Gel permeation chromatograph [Model "HLC-8120GPC", manufactured by Tosoh Corporation]

[0116] [2] Column: "TSKgel G6000PWxl" and "TSKgel G3000PWxl" [both manufactured by Tosoh Corporation] are connected in series.

[0117] [3] Eluent: A liquid prepared by dissolving 0.5 wt% of sodium acetate in methanol / water = 30 / 70 (volume ratio).

[0118] [4] Standard substance: Polyethylene glycol (hereinafter simply referred to as PEG)

[0119] [5] Injection conditions: Sample concentration 0.25 wt%, column temperature 40 °C

[0120] As the monomers in the above polymers, monosaccharides [α-glucose, β-glucose, uronic acids (mannuronic acid, guluronic acid, etc.)], (meth)acrylic acid monomers [C3-C10 (meth)acrylic acid monomers; acrylic acid, etc.], (alkyl)alkoxysilanes [C4-C40 dialkyldialkoxysilanes; for example, diethoxydimethylsilane, dimethoxydimethylsilane, etc.], alkylene oxides [C2-C4 alkylene oxides; ethylene oxide, propylene oxide, butylene oxide, etc.] and the like can be mentioned.

[0121] It should be noted that in the present invention, (meth)acrylic acid means acrylic acid and / or methacrylic acid.

[0122] It should be noted that in the present invention, (alkyl)alkoxysilane means alkoxysilane and / or alkylalkoxysilane.

[0123] Specific examples of the above-mentioned polymers include carboxyalkyl cellulose and its salts (carboxymethyl ethyl cellulose, sodium carboxymethyl cellulose, etc.), alkyl cellulose and its salts (methyl cellulose 4000, etc.), sodium alginate, xanthan gum, starch-sodium acrylate graft copolymer, and polyalkylene glycol (polyethylene glycol such as PEG20000, etc.), polydimethylsiloxane (A), alkylene oxide adducts of aliphatic alcohols (B), etc.

[0124] As the nonvolatile component, one of the above-mentioned polymers may be used alone, or two or more thereof may be used in combination.

[0125] For example, polydimethylsiloxane (A) and an alkylene oxide adduct of an aliphatic alcohol (B) may be used together. In this case, the weighted average HLB value of polydimethylsiloxane (A) and the alkylene oxide adduct of an aliphatic alcohol (B) [the weighted average based on the weight ratio of polydimethylsiloxane (A) and the alkylene oxide adduct of an aliphatic alcohol (B)] is 7 or more.

[0126] The base (Y) may contain only a nonvolatile component, or may contain a volatile component in addition to the nonvolatile component.

[0127] Hereinafter, as an example of the base (Y), a composition containing polydimethylsiloxane (A) and an alkylene oxide adduct of an aliphatic alcohol (B) as nonvolatile components and water (additive described later) as a volatile component will be described.

[0128] The polydimethylsiloxane (A) includes those having a structure having a dimethylsiloxane unit {-(CH3)2SiO-} as a repeating unit, and specifically, those represented by the following general formula (1) and the like are exemplified.

[0129] CH3-[(CH3)2SiO] n -Si-(CH3)3(1)

[0130] In the general formula (1), n ​​is the number average number of dimethylsiloxane units and represents a number of 60 to 500, and is not limited to an integer.

[0131] In the general formula (1), n ​​is preferably a number of 100 to 450, more preferably a number of 150 to 400, from the viewpoint of spreadability.

[0132] As the polydimethylsiloxane (A), for example, “100CST (n=85)”, “350CST (n=200)”, and “1000CST (n=350)” of DOW CORNING(R) Q7-9120 SILICONE FLUID manufactured by Dow Corning Toray Co., Ltd. are commercially available.

[0133] As the polydimethylsiloxane (A), from the viewpoint of the sustainability of the effect of the bacterial flora improving agent, the polydimethylsiloxane represented by the above-mentioned general formula (1) is preferred.

[0134] As the alkylene oxide adduct (B) of an aliphatic alcohol, those represented by the following general formula (2) are preferred from the viewpoint of spreadability.

[0135] R 1 -(OA) m -OH(2)

[0136] In the general formula (2), R 1 represents an alkyl group having 8 to 18 carbon atoms or an alkenyl group having 8 to 18 carbon atoms, OA represents an oxyalkylene group having 2 to 4 carbon atoms, and m represents the number of moles of the oxyalkylene group added, which is a number of 1 to 50 and is not limited to an integer.

[0137] In the general formula (2), R 1 It represents an alkyl group having 8 to 18 carbon atoms or an alkenyl group having 8 to 18 carbon atoms.

[0138] The alkyl group having 8 to 18 carbon atoms includes a linear alkyl group having 8 to 18 carbon atoms and a branched alkyl group having 8 to 18 carbon atoms.

[0139] Examples of the linear alkyl group having 8 to 18 carbon atoms include n-octyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl and n-octadecyl.

[0140] Examples of the branched alkyl group having 8 to 18 carbon atoms include 2-ethylhexyl, isodecyl, isoundecyl, isododecyl, isotridecyl, isotetradecyl, isopentadecyl, isohexadecyl, isoheptadecyl and isooctadecyl.

[0141] The alkenyl group having 8 to 18 carbon atoms includes a linear alkenyl group having 8 to 18 carbon atoms and a branched alkenyl group having 8 to 18 carbon atoms.

[0142] Examples of the straight-chain alkenyl group having 8 to 18 carbon atoms include n-octenyl, n-dodecenyl, n-hexadecenyl and n-octadecenyl.

[0143] Examples of the branched alkenyl group having 8 to 18 carbon atoms include isodecenyl, isododecenyl and isooctadecenyl.

[0144] As R 1 In view of spreadability, a linear alkyl group having 8 to 18 carbon atoms is preferred, and a linear alkyl group having 10 to 18 carbon atoms is more preferred.

[0145] In the general formula (2), examples of OA include ethylene oxide, propylene oxide, and butylene oxide.

[0146] As OA, ethylene oxide is preferred from the viewpoint of spreadability.

[0147] In the general formula (2), m is preferably a number of 3 to 40 from the viewpoint of spreadability.

[0148] In the alkylene oxide adduct (B) of an aliphatic alcohol, the HLB value is preferably 8.5 to 11.0, more preferably 9.0 to 10.5, from the viewpoint of spreadability.

[0149] The weight ratio {(A) / (B)} of the polydimethylsiloxane (A) to the alkylene oxide adduct of an aliphatic alcohol (B) is preferably 85 / 15 to 40 / 60, more preferably 80 / 20 to 35 / 65, from the viewpoint of spreadability and duration of effect.

[0150] From the perspective of the sustainability of the effect, the total content of the polydimethylsiloxane (A) and the alkylene oxide adduct of the aliphatic alcohol (B) is preferably 0.1 to 85% by weight, more preferably 1 to 85% by weight, further preferably 5 to 85% by weight, particularly preferably 40 to 85% by weight, and most preferably 50 to 80% by weight, based on the weight of the bacterial flora improving agent.

[0151] From the viewpoint of the sustainability of the effect, the total content of the polydimethylsiloxane (A) and the alkylene oxide adduct of an aliphatic alcohol (B) is preferably 30 to 99% by weight, more preferably 50 to 99% by weight, particularly preferably 80 to 99% by weight, and most preferably 90 to 99% by weight, based on the total weight of the non-volatile components in the substance (X) and the base (Y).

[0152] The bacterial flora improving agent contains only four components, namely, substance (X), polydimethylsiloxane (A), alkylene oxide adduct of aliphatic alcohol (B) and water. When three components other than substance (X) are used as base (Y), from the aspect of the sustainability of the effect, the total content of polydimethylsiloxane (A) and alkylene oxide adduct of aliphatic alcohol (B) is preferably 1 to 85% by weight, more preferably 5 to 85% by weight, particularly preferably 40 to 85% by weight, and most preferably 50 to 80% by weight, based on the weight of the base (Y).

[0153] Examples of a method for producing a base (Y) containing polydimethylsiloxane (A), an alkylene oxide adduct of an aliphatic alcohol (B), and water include a method comprising the step (I) of mixing polydimethylsiloxane (A), an alkylene oxide adduct of an aliphatic alcohol (B), and water.

[0154] The polydimethylsiloxane (A) and the aliphatic alcohol alkylene oxide adduct (B) are preferably mixed in advance. In the step of mixing the polydimethylsiloxane (A) and the aliphatic alcohol alkylene oxide adduct (B), the mixing temperature is preferably 20° C. to 70° C., more preferably 25° C. to 65° C., from the viewpoint of emulsification.

[0155] In step (I), the weight ratio {(A) / (B)} of the polydimethylsiloxane (A) to the alkylene oxide adduct of an aliphatic alcohol (B) is preferably 85 / 15 to 40 / 60, more preferably 80 / 20 to 35 / 65, from the viewpoint of spreadability and durability of the effect.

[0156] In step (I), the temperature of water is preferably 20°C to 70°C, more preferably 25 to 65°C, from the viewpoint of emulsification.

[0157] In step (I), the amount of water is preferably 15 to 99% by weight, more preferably 20 to 99% by weight, based on the total weight of the polydimethylsiloxane (A), the alkylene oxide adduct of an aliphatic alcohol (B), and water, from the viewpoint of the sustainability of the effect.

[0158] In step (I), stirring is preferably performed using a planetary mixer from the viewpoint of gelation.

[0159] The rotation speed of the planetary mixer is preferably 10 to 70 rpm for rotation and 5 to 40 rpm for revolution, and more preferably 15 to 60 rpm for rotation and 10 to 35 rpm for revolution, from the viewpoint of uniformity.

[0160] Examples of the stirring blade include a propeller and a gate-type stirring blade. From the viewpoint of uniformity, a gate-type stirring blade is preferred.

[0161] In step (I), when mixing the mixture of polydimethylsiloxane (A) and the alkylene oxide adduct of aliphatic alcohol (B) with water, water is preferably added in 5 to 50 parts, more preferably 10 to 40 parts, from the viewpoint of gelation.

[0162] When mixing with water in step (I), from the viewpoint of gelation, it is preferred to add one part of water, confirm that the appearance is sufficiently uniform, and then add the next part of water.

[0163] When the flora improving agent of the present invention is used to improve the flora balance of the oral cavity, it preferably contains (YA) and / or (YB) as a non-volatile component from the viewpoint of the sustainability of the effect, and it is more preferred to use (YA) and (YB) in combination.

[0164] <(YA)>

[0165] (YA) is a polymer (such as sodium carboxymethylcellulose, xanthan gum, and sodium alginate) having an anionic group (such as a carboxyl group and a carboxylate group) and a weight average molecular weight of 50,000 to 3,000,000 (preferably 100,000 to 2,000,000), and may be a mixture of two or more polymers.

[0166] <(YB)>

[0167] (YB) is a component obtained by excluding the above-mentioned (YA) from components having an HLB value of 7 or more, and satisfies the following conditions (1) and / or (2).

[0168] (1) The viscosity of the liquid after dilution with water in a manner such that the concentration of (YB) is 1% by weight (measured by the same method as the viscosity of the bacterial flora improving agent described later measured at 37°C using a cone-plate rotational viscometer) is greater than 1 mPa·s and less than 500 mPa·s (preferably greater than 5 mPa·s and less than 450 mPa·s).

[0169] (2) The weight average molecular weight is 10,000 to 80,000 (preferably 15,000 to 50,000).

[0170] (YB) may be a mixture of two or more components.

[0171] When (YA) and (YB) are used together, the ratio of the weight of (YA) to the weight of (YB) [(YA) / (YB)] is preferably 0.001 to 0.2, more preferably 0.001 to 0.1.

[0172] [Other ingredients]

[0173] The microflora improving agent of the present invention may contain components (additives) other than the above-mentioned substance (X) and non-volatile components. The additives may be added separately from the base (Y) or may be appropriately contained in the base (Y).

[0174] Examples of the additives include lubricants such as wax, antioxidants, ultraviolet absorbers, defoamers, preservatives, fragrances, and solvents [water and organic solvents (ethanol, etc.)].

[0175] When the following bactericidal components are contained as the above-mentioned additive, the total weight of the bactericidal components is preferably 2% by weight or less based on the total weight of the substance (X) from the viewpoint of the effect of the flora improving agent.

[0176] The above-mentioned bactericidal ingredient is one or more selected from the group consisting of glycyrrhizic acid (salt), β-glycyrrhetinic acid, isopropyl methylphenol, cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, alkyldiaminoethylglycine chloride solution, chlorhexidine hydrochloride, chlorhexidine hydrochloride, triclosan, lysozyme chloride, cypermethrin, sodium lauroyl sarcosinate and sodium dodecyl sulfate.

[0177] The content of the solvent in the flora improving agent is not particularly limited as long as it is within the range of the viscosity and mixing consistency of the flora improving agent described below, and is preferably 5 to 99% by weight based on the total weight of the flora improving agent.

[0178] The water content in the flora improving agent is preferably 5 to 99 wt %, more preferably 30 to 99 wt % relative to the total weight of the flora improving agent from the viewpoint of spreadability and flora balance improvement effect.

[0179] When the flora-improving agent contains water, it is preferred that the flora-improving agent be uniform (not separated into two or more phases) when visually observed after being allowed to stand at 25° C. for 10 minutes after being produced by the method described below.

[0180] The upper limit of the content of the additives other than the solvent in the flora improving agent is preferably 10 wt % or less, more preferably 8 wt % or less, and particularly preferably 1 wt % or less, based on the weight of the nonvolatile components in the flora improving agent.

[0181] The lower limit of the content of the additives other than the solvent in the bacterial flora improving agent is not particularly limited, but may be 0.1% by weight or more based on the weight of the nonvolatile components in the bacterial flora improving agent.

[0182] [Bacteria flora improving agent]

[0183] The content (weight ratio) of the substance (X) is preferably 0.01 to 5% by weight, more preferably 0.05 to 3% by weight, based on the weight of the bacterial flora improving agent.

[0184] From the perspective of appropriately imparting a high pathogenic bacteria inhibitory effect, the lower limit of the content (weight ratio) of substance (X) is preferably 0.01% by weight, and more preferably 0.05% by weight, based on the weight of the bacterial flora improving agent of the present invention.

[0185] From the viewpoint of appropriately maintaining non-pathogenic resident bacteria, the upper limit of the content of substance (X) is preferably 5% by weight, and more preferably 3% by weight, based on the weight of the flora improving agent of the present invention.

[0186] It should be noted that when a hydroxycarboxylic acid (a compound having a hydroxyl group and a carboxyl group, particularly citric acid) is used as the compound (X2), from the perspective of the effect of the flora improving agent, the weight ratio of the hydroxycarboxylic acid as the compound (X2) is preferably 1 weight % or more based on the weight of the flora improving agent.

[0187] The lower limit of the content of substance (X) is preferably 1% by weight, and the lower limit is more preferably 2% by weight, relative to the weight of the non-volatile components in the microflora improving agent. In addition, the upper limit of the content of substance (X) is preferably 200% by weight, and the upper limit is more preferably 150% by weight, relative to the weight of the non-volatile components in the microflora improving agent. The content of substance (X) is preferably 1 to 200% by weight, and more preferably 2 to 150% by weight, relative to the weight of the non-volatile components in the microflora improving agent.

[0188] By containing the substance (X) in the above range, it is possible to appropriately provide the effect of having a high inhibitory effect on pathogenic bacteria while maintaining non-pathogenic resident bacteria, and to maintain the above performance for a long period of time.

[0189] When the microflora improving agent of the present invention contains zinc atoms and / or magnesium atoms (including the case of containing compounds containing these atoms (zinc oxide, etc.)), from the perspective of the effect of the microflora improving agent, the ratio of the total weight of zinc atoms and magnesium atoms is preferably 0.5 weight % or less based on the total weight of substance (X).

[0190] In addition, when the microflora improving agent of the present invention contains zinc atoms and / or magnesium atoms (including the case of containing compounds containing these atoms), from the perspective of the effect of the microflora improving agent, the ratio of the total weight of zinc atoms and magnesium atoms based on the weight of the microflora improving agent is preferably 0.005 weight % or less.

[0191] The mixed consistency of the flora improving agent of the present invention measured in accordance with JIS K 2220 is 100 to 400. If it is less than 100, the inhibitory effect on pathogenic bacteria is poor. If it is more than 400, it becomes difficult to maintain non-pathogenic resident bacteria.

[0192] The mixed consistency of the bacterial flora improving agent of the present invention measured in accordance with JIS K 2220 is preferably 100 to 300 from the viewpoint of the sustainability of the effect.

[0193] The viscosity of the bacterial flora improving agent of the present invention measured at 37° C. using a cone-plate rotational viscometer is 1 to 4,000 Pa·s.

[0194] Specifically, it is the viscosity measured by the following measurement method.

[0195] <Measurement Conditions>

[0196] Device: MCR302 (manufactured by Anton Paar)

[0197] Fixture: CP-25 (cone plate with a diameter of 25 mm)

[0198] Pitch: 1mm

[0199] Temperature: 37°C

[0200] Strain speed: 0.5 1 / s (rotation speed: 0.6rpm)

[0201] <Measurement method>

[0202] A sample of about 1.5 g was placed on the sample stand and sandwiched with CP-25, with the interval between the cone and the plate set to 1 mm, and the exuded sample was scraped off.

[0203] After 1 minute of temperature adjustment at 37°C, the rotation speed was changed from 0.1 to 10 rpm (20 points were plotted at measurement intervals of 10 seconds to 1 second). The viscosity value at a strain rate of 0.5 1 / s (rotation speed: 0.6 rpm) was recorded and used as the viscosity of the flora improving agent.

[0204] When the viscosity of the microflora improving agent is less than 1 Pa·s, the sustainability of the effect of the microflora improving agent is poor. When the viscosity of the microflora improving agent is greater than 4,000 Pa·s, the inhibitory effect on pathogenic bacteria is poor.

[0205] From the viewpoint of the sustainability of the effect, the viscosity of the bacterial flora improving agent is preferably 10 to 4,000 Pa·s, more preferably 1,000 to 4,000 Pa·s.

[0206] In addition, from the viewpoint of spreadability, the viscosity of the flora improving agent is preferably 2,000 to 3,700 Pa·s.

[0207] From the viewpoint of the effect of improving the balance of the bacterial flora, the pH of the liquid obtained by diluting the bacterial flora improving agent of the present invention with water (ion exchange water, etc.) so that the concentration is 1% by weight is preferably 6 to 8.

[0208] The pH can be measured at 25°C using a pH meter.

[0209] The bacterial flora improving agent of the present invention can be produced by mixing the components and uniformly mixing them at room temperature or, if necessary, by heating (for example, 30 to 70° C.). The mixing order and mixing method of the components are not particularly limited.

[0210] [How to use]

[0211] The flora improving agent of the present invention is a flora improving agent for improving the flora of mucous membranes, skin and / or nails, and can be used by applying it to the affected area [mucous membrane {oral cavity (tongue, gums, gums, etc.), intestines, eyes, etc.}, skin, nails, etc.] or the periphery of the affected area with fingers, etc., so that the flora improving agent is retained in the affected area, and is particularly preferably suitable for use on mucous membranes.

[0212] For example, when the flora improving agent of the present invention is applied to the oral mucosa (tongue, gums, gums, etc.), it can be expected to have a preventive effect on periodontal disease that progresses through the stages of gingivitis and periodontitis.

[0213] The flora improving agent of the present invention can also be used as medicines, medical devices (medical adhesives and wound healing materials, etc.), quasi-drugs, cosmetics, and foods by using non-volatile components corresponding to the purpose, and the above uses can improve the flora balance of the application site. In addition, as the above uses, specifically, toothpastes, oral gels, oral care foods, supplements, pet care products, and nail care products can be cited.

[0214] The following matters are disclosed in this specification.

[0215] The present disclosure (1) relates to a flora improving agent for improving the flora of mucous membranes, skin and / or nails, comprising a substance (X) and a base (Y) containing a non-volatile component, wherein the substance (X) is at least one selected from the group consisting of a compound (X1) having two or more hydroxyl groups contained in an oxyacid group and a salt thereof, a compound (X2) having one hydroxyl group contained in an oxyacid group and a salt thereof, a heterocyclic compound (X3) having no oxyacid group and a salt thereof, and a ketone (X4) having no oxyacid group, wherein:

[0216] The total mass ratio of the oxyacid groups, hydroxyl groups not contained in the oxyacid groups, carbonyl groups not contained in the oxyacid groups, carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton of the compound (X1) is 45% by mass or more, based on the molecular weight of the compound (X1),

[0217] The compound (X2) contains an atom having an unshared electron pair (excluding atoms contained in an oxoacid group, and atoms contained in an amino group that does not constitute an imidazole skeleton and an amino group that does not constitute a pyridine skeleton).

[0218] The total mass ratio of the oxyacid groups, hydroxyl groups not contained in the oxyacid groups, carbonyl groups not contained in the oxyacid groups, carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton of the compound (X2) is 55% by mass or more, based on the molecular weight of the compound (X2);

[0219] The heterocyclic compound (X3) has an imidazole skeleton or a pyridine skeleton, and a hydroxyl group and / or a carbonyl group, or has two or more skeletons selected from imidazole skeletons and pyridine skeletons,

[0220] The above ketone (X4) has a linear β-diketone structure,

[0221] The molecular weight of substance (X) is 550 or less,

[0222] The HLB value of the non-volatile component is 7 or more,

[0223] The microflora improving agent meets the following conditions (i) to (ii):

[0224] (i) The above-mentioned flora improving agent has a mixing consistency of 100 to 400 as measured in accordance with JIS K 2220.

[0225] (ii) The above-mentioned bacterial flora improving agent has a viscosity at 37° C. of 1 to 4,000 Pa·s as measured by a cone-plate rotational viscometer.

[0226] The present disclosure (2) relates to the microflora improving agent described in the present disclosure (1), wherein the pH of the liquid obtained by diluting the microflora improving agent with water so that the concentration of the microflora improving agent is 1% by weight is 6 to 8.

[0227] The present disclosure (3) relates to the microflora improving agent described in the present disclosure (1) or (2), wherein the weight ratio of the substance (X) is 0.01 to 5 weight % based on the weight of the microflora improving agent.

[0228] Example

[0229] The present invention is further described below by way of examples and comparative examples, but the present invention is not limited thereto. Hereinafter, unless otherwise specified, part means part by weight, and % means % by weight.

[0230] <Examples 1 to 44 and Comparative Examples 1 to 16: Production of Bacterial Flora Improving Agents>

[0231] The substance (X) [or (X')], the base (Y) [or (Y')], and ion-exchanged water were mixed at 25°C so as to have the concentrations (weight %) described in Tables 1-1 to 1-6.

[0232] In addition, the viscosity and mixed consistency of each flora improving agent were measured by the method described in the specification, and the results are recorded in Tables 1-1 to 1-6. In addition, the pH of the liquid obtained by diluting with ion exchange water so that the concentration of each flora improving agent becomes 1% by weight is also recorded in Tables 1-1 to 1-6. The mixed consistency of the flora improving agent of Comparative Example 14 was greater than 400 and could not be measured.

[0233] The viscosity of the liquid diluted with ion exchange water so that the concentration of the nonvolatile component in each base (Y) became 1 wt % was also measured by the method described in the specification, and is shown in Table 2 together with the HLB value and weight average molecular weight of the nonvolatile component.

[0234] <Description of Each Component>

[0235] The raw materials corresponding to the components used in Examples and Comparative Examples are as follows.

[0236] [Substance (X) or (X')]

[0237] (X-1): pentasodium triphosphate [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxyacid groups to the molecular weight of triphosphate: 88 mass %]

[0238] (X-2): Acetylacetone [manufactured by Nacalai Tesque Co., Ltd., ratio of total mass of carbonyl groups to molecular weight of acetylacetone: 56 mass %]

[0239] (X-3): Benzoylacetone [manufactured by Merck, ratio of the total mass of carbonyl groups to the molecular weight of benzoylacetone: 35 mass %]

[0240] (X-4): Levulinic acid [manufactured by Tokyo Chemical Industry Co., Ltd., ratio of the total mass of the oxyacid group and the carbonyl group to the molecular weight of levulinic acid: 63 mass %]

[0241] (X-5): Sodium tungstate dihydrate [Na2WO4·2H2O, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., the ratio of the total mass of oxyacid groups to the molecular weight of tungstic acid: 100% by mass. It should be noted that the weight ratio of substance (X) (Na2WO4) contained in (X-5) is 89% by weight based on the weight of (X-5).]

[0242] (X-6): Glycylglycine [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of the oxyacid group and the carbonyl group to the molecular weight of glycylglycine: 55 mass %]

[0243] (X-7): Glutamic acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxoacid groups to the molecular weight of glutamic acid: 61 mass %]

[0244] (X-8): Malic acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxyacid groups and hydroxyl groups to the molecular weight of malic acid: 80 mass %]

[0245] (X-9): Citric acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxyacid groups and hydroxyl groups to the molecular weight of citric acid: 79 mass %]

[0246] (X-10): Gluconic acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxygen-containing acid groups and hydroxyl groups to the molecular weight of gluconic acid: 66 mass %]

[0247] (X-11): Glucuronic acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxygen-containing acid groups and hydroxyl groups to the molecular weight of glucuronic acid: 58 mass %]

[0248] (X-12): Ethylenediaminetetraacetic acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxyacid groups to the molecular weight of ethylenediaminetetraacetic acid: 62 mass %]

[0249] (X-13): Iminodiacetic acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxoacid groups to the molecular weight of iminodiacetic acid: 68 mass %]

[0250] (X-14): 8-Hydroxyquinoline [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of carbon atoms, nitrogen atoms and hydroxyl groups contained in the pyridine skeleton to the molecular weight of 8-hydroxyquinoline: 63 mass %]

[0251] (X-15): Tartaric acid [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., ratio of the total mass of oxygen-containing acid groups and hydroxyl groups to the molecular weight of tartaric acid: 83 mass %]

[0252] (X-16): Adenosine triphosphate disodium trihydrate [manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., the ratio of the total mass of the oxygen-containing acid group, the hydroxyl group, and the carbon atoms and nitrogen atoms contained in the imidazole skeleton to the molecular weight of adenosine triphosphate: 61% by mass. It should be noted that the weight ratio of the substance (X) (adenosine triphosphate disodium) contained in (X-16) is 91% by weight based on the weight of (X-16).]

[0253] (X'-1): Benzalkonium chloride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0254] (X'-2): Cetylpyridinium chloride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0255] [Base (Y) or (Y')]

[0256] (Y-1): Carboxymethyl ethyl cellulose [trade name: CMEC, manufactured by Sanyo Chemical Industries, Ltd.]

[0257] (Y-2): Sodium carboxymethyl cellulose (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0258] (Y-3): Sodium alginate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0259] (Y-4): Xanthan gum (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0260] (Y-5): Starch-sodium acrylate graft copolymer [Product name: Sun Fresh ST100, manufactured by Sanyo Chemical Industries, Ltd.]

[0261] (Y-6): PEG20000 [manufactured by Sanyo Chemical Industries, Ltd.]

[0262] (Y-7-1) to (Y-7-4): Substances produced in Production Examples 1 to 4, respectively

[0263] (Y'-1): White vaseline (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0264] (Y-8): Methylcellulose 4000 (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)

[0265] In addition, the amount (g) of magnesium captured per 100g of the substance (X) when measured by the ion electrode method for each substance (X) was measured by the following method. For (X-5), the amount of magnesium captured per 100g of Na2WO4 contained in (X-5) was measured. In addition, for (X-16), the amount of magnesium captured per 100g of disodium adenosine triphosphate contained in (X-16) was measured.

[0266] In the above-mentioned measurement by the ion electrode method, the measurement was carried out using 2 mM of the substance (X) in a 1 mM MgCl 2 aqueous solution at 20° C. and pH 7.

[0267] The results are shown in Table 3.

[0268] <Production Example 1: Production of Base (Y-7-1)>

[0269] 46.9 parts of polydimethylsiloxane (Toray Dow Corning Co., Ltd.: Q7-9120 SILICONE FLUID, 1000CST (n=350), HLB value: 5.1) and 23.1 parts of ethylene oxide 15 mol adduct of cetyl alcohol (HLB value: 12.2) were placed in a planetary mixer PLM-15 manufactured by Inoue Seisakusho equipped with a gate-type stirring blade, heated to 37° C., and then adjusted to 37° C. while stirring the planetary mixer at 20 rpm for rotation and 50 rpm for revolution. While checking the appearance, 40 parts of warm water adjusted to 37° C. were slowly mixed therein to prepare a base (Y-7-1).

[0270] <Production Example 2: Production of Base (Y-7-2)>

[0271] In Production Example 1, a base (Y-7-2) was prepared in the same manner except that “630 parts of warm water” was used instead of “40 parts of warm water”.

[0272] <Production Example 3: Production of Base (Y-7-3)>

[0273] In Production Example 1, a base (Y-7-3) was prepared in the same manner except that "3430 parts of warm water" was used instead of "40 parts of warm water".

[0274] <Production Example 4: Production of Base (Y-7-4)>

[0275] In Production Example 1, a base (Y-7-4) was prepared in the same manner except that "20 parts of warm water" was used instead of "40 parts of warm water".

[0276] <Confirmation test for selective bacterial growth inhibition>

[0277] In the test, Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella intermedia, Trichophyton rubrum, Trichophyton mentagrophytes, Staphylococcus aureus, Candida albicans, and Candida glabrata were used as pathogenic bacteria, and Streptococcus salivarius and Staphylococcus epidermidis were used as non-pathogenic bacteria.

[0278] As the culture medium for culturing each bacteria, modified GAM broth "Nissui" (manufactured by Nissui Pharmaceutical Co., Ltd.) supplemented with 1 μg / mL menadione was used for Porphyromonas gingivalis, modified GAM broth "Nissui" was used for Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus salivarius, Sabouraud dextrose broth (manufactured by Nippon Pharmaceutical Co., Ltd.) was used for Trichophyton rubrum and Trichophyton mentagrophytes, LB medium (manufactured by Becton-Dickinson) was used for Staphylococcus aureus and Staphylococcus epidermidis, and Candida albicans and Candida glabrata were used. glabrata), and YM medium (manufactured by Sigma) was used.

[0279] For Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia, the cultures were cultured under anaerobic conditions, and for Streptococcus salivarius, Trichophyton rubrum, Trichophyton mentagrophytes, Staphylococcus aureus, Staphylococcus epidermidis, Candida albicans, and Candida glabrata, the cultures were cultured under aerobic conditions.

[0280] 50 mg of each bacterial flora improving agent prepared according to the composition described in Table 1-1 to Table 1-6 was dispensed into each well of a 24-well plate.

[0281] For each strain cultured at 37°C under anaerobic conditions overnight using the above-mentioned medium, the culture medium was diluted so that the absorbance at 600nm was 0.2, and 500 μL was dispensed into a 24-well plate to which a flora improving agent was added, and then AneroPack Anaerobic 10% (manufactured by Mitsubishi Gas Chemical Co., Ltd.) was used to statically culture at 37°C under anaerobic conditions. In addition, for each strain cultured at 37°C under aerobic conditions overnight using the above-mentioned medium with shaking, the culture medium was diluted so that the absorbance at 600nm was 0.2, and 500 μL was dispensed into a 24-well plate to which a flora improving agent was added, and then statically cultured at 37°C. After 48 hours, the plates were collected and the absorbance at 600nm was measured to evaluate the proliferation of each bacterium.

[0282] The growth inhibition effect was expressed as a relative value when the turbidity when the same weight of ion exchange water was used instead of each flora improving agent was taken as 1. The results are shown in Tables 1-1 to 1-6.

[0283] When the flora improving agent of the present invention is applied to the oral cavity, if the proliferation of Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia is inhibited compared to the case where the flora improving agent is not added, and the proliferation of Streptococcus salivarius does not change compared to the case where the flora improving agent is not added, then the proliferation is inhibited in a bacteria-selective manner.

[0284] For example, the relative value may be in the following range.

[0285] The test results for Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia are 0.01 to 0.30 (preferably 0.01 to 0.15), and the test results for Streptococcus salivarius are 0.8 to 1.2.

[0286] In addition, when the flora improving agent of the present invention is applied to the skin and nails, if the proliferation of Trichophyton rubrum, Trichophyton mentagrophytes, Staphylococcus aureus, Candida albicans, and Candida glabrata is inhibited compared to the case where the flora improving agent is not added, and the proliferation of Staphylococcus epidermidis does not change compared to the case where the flora improving agent is not added, then the proliferation is inhibited in a bacteria-selective manner.

[0287] For example, the relative value may be in the following range.

[0288] The test results for Trichophyton rubrum, Trichophyton mentagrophytes, and Staphylococcus aureus are 0.01 to 0.30 (preferably 0.01 to 0.15), and the test results for Staphylococcus epidermidis are 0.8 to 1.2.

[0289] <Test for inhibition of protease production by pathogenic bacteria>

[0290] In the test, Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia were used as pathogenic bacteria. As the culture medium for culturing each bacterium, modified GAM broth "Nissui" (manufactured by Nissui Pharmaceutical Co., Ltd.) supplemented with 1 μg / mL menadione was used for Porphyromonas gingivalis, and modified GAM broth "Nissui" was used for Fusobacterium nucleatum and Prevotella intermedia.

[0291] 50 mg of each flora improver prepared according to the composition described in Table 1-1 to Table 1-6 was dispensed into each well of a 24-well plate. For each strain cultured overnight at 37°C under anaerobic conditions using the above-mentioned culture medium, each culture medium was diluted so that the absorbance at 600 nm was 0.2, and 500 μL was dispensed into each 24-well plate to which the flora improver was added, and then AneroPack Anaerobic 10% (manufactured by Mitsubishi Gas Chemical Co., Ltd.) was used to statically culture at 37°C under anaerobic conditions. After 48 hours, the plate was recovered and centrifuged at 4°C and 10,000 rpm for 5 minutes to recover each culture supernatant. The activity of the protease contained in the culture supernatant was evaluated using the Amplite Protease Activity Assay Kit (manufactured by AAT Bioquest).

[0292] The production of protease was expressed as a relative value when the protease activity value when the same weight of ion-exchanged water was used instead of each flora improving agent was taken as 1. The results are shown in Tables 1-1 to 1-6.

[0293] Here, it is known that protease is one of the toxin components produced by pathogenic bacteria, and the lower the protease activity value is, the more the protease production is inhibited.

[0294] <Sustainability evaluation of the effect based on the halo test>

[0295] [Preparation of agar medium for inhibition zone test]

[0296] In the test, Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella intermedia, Trichophyton rubrum, Trichophyton mentagrophytes, Staphylococcus aureus, Candida albicans, and Candida glabrata were used as pathogenic bacteria, and Streptococcus salivarius and Staphylococcus epidermidis were used as non-pathogenic bacteria.

[0297] As the culture medium for culturing each bacteria, modified GAM broth "Nissui" (manufactured by Nissui Pharmaceutical Co., Ltd.) supplemented with 1 μg / mL menadione was used for Porphyromonas gingivalis, modified GAM broth "Nissui" was used for Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus salivarius, Sabouraud dextrose broth (manufactured by Nippon Pharmaceutical Co., Ltd.) was used for Trichophyton rubrum and Trichophyton mentagrophytes, LB medium (manufactured by Becton-Dickinson) was used for Staphylococcus aureus and Staphylococcus epidermidis, and Candida albicans and Candida glabrata were used. glabrata) and YM medium (manufactured by Sigma).

[0298] Each strain was cultured overnight at 37°C under anaerobic or aerobic conditions using the above medium, and the concentration of each strain was 1.0 × 10 5 After preparing the bacterial solution in the CFU / ml method, 100 μL of the bacterial solution was inoculated on the agar medium of each culture medium component and evenly spread with a smear stick.

[0299] [Inhibition zone test]

[0300] The test was carried out by inoculating 200 μL of each flora improver prepared according to the composition described in Table 1-1 to Table 1-6 as a test sample on an agar medium coated with bacteria. The bacteria cultured under anaerobic conditions were cultured at 37°C for 24 hours using AneroPack Anaerobic 10% (manufactured by Mitsubishi Gas Chemical Co., Ltd.). The bacteria cultured under aerobic conditions were cultured at 37°C for 24 hours. In the evaluation of the sustainability of the inhibitory effect on the proliferation of pathogenic bacteria, for samples evaluated as × after 24 hours of culture, the cultivation of pathogenic bacteria was terminated, and for other samples, the cultivation at 37°C was continued until 1 week after cultivation. For samples evaluated as △ after 1 week of cultivation, the cultivation of pathogenic bacteria was terminated, and for other samples, the cultivation at 37°C was further continued until 2 weeks after cultivation. In the evaluation of the sustainability of the effect on non-pathogenic bacteria, all bacteria were continued until 2 weeks after cultivation.

[0301] It should be noted that the determination of the inhibition zone is to measure the length from the end of the test sample application area to the end of the inhibition zone. If it is greater than 0 mm, it is determined that the inhibition zone is confirmed, and if it is 0 mm, it is determined that the inhibition zone is not confirmed.

[0302] In the evaluation of the inhibitory effect on the proliferation of pathogenic bacteria, the confirmation of the inhibition zone means that there is a proliferation inhibitory effect, and the failure to confirm the inhibition zone means that there is no proliferation inhibitory effect. In addition, in the evaluation of the effect on non-pathogenic bacteria, the failure to confirm the inhibition zone means that the proliferation is not inhibited (the proliferation is not affected), and the confirmation of the inhibition zone means that the proliferation is inhibited. Here, the continuous evaluation of the inhibitory effect on the proliferation of pathogenic bacteria ("Continuous evaluation (pathogenic bacteria)") and the continuous evaluation of the effect on non-pathogenic bacteria ("Continuous evaluation (non-pathogenic bacteria)") are respectively performed according to the following criteria. The evaluation results are shown in Tables 1-1 to 1-6.

[0303] <Sustainability Evaluation (Pathogenic Bacteria)>

[0304] ◎: Inhibition zones were observed in the evaluation after 24 hours, 1 week, and 2 weeks of culture.

[0305] ○: Inhibition zones were observed in the evaluations after 24 hours of culture and 1 week, but were not observed (disappeared) in the evaluations after 2 weeks.

[0306] △: In the evaluation after 24 hours of culture, the inhibition zone was confirmed, but in the evaluation after 1 week, the inhibition zone disappeared.

[0307] ×: No inhibition zone was observed in the evaluation after 24 hours of culture.

[0308] <Sustainability Evaluation (Non-pathogenic Bacteria)>

[0309] ◎: No inhibition zone was observed after 24 hours, 1 week, and 2 weeks of culture.

[0310] ○: In the evaluation after 24 hours of culture, an inhibition zone was observed, but in the evaluation after 1 week and 2 weeks, no inhibition zone was observed.

[0311] △: Inhibition zones were observed in the evaluation after 24 hours and 1 week of culture, but no inhibition zones were observed in the evaluation after 2 weeks.

[0312] ×: Inhibition zones were observed in the evaluation after 24 hours, 1 week, and 2 weeks of culture.

[0313] <Evaluation of Spreadability>

[0314] A 10 cm square piece of leather was immersed in a 15 cm diameter petri dish with 80 cc of artificial saliva (0.844 g / L sodium chloride, 1.2 g / L potassium chloride, 0.146 g / L calcium chloride hydrate, 0.052 g / L magnesium chloride, 0.342 g / L potassium dihydrogen phosphate) at 37°C for 10 minutes. After 10 minutes, the moisture on the leather surface was removed with gauze. Then, 0.5 g of each flora improving agent was placed on the finger and spread on the leather. Ten people conducted a sensory test of the smoothness when spreading and the residual size on the finger. The results of the following evaluations are shown in Tables 1-1 to 1-6.

[0315] ◎: More than 7 people felt that it was smooth when spread and no bacterial flora improver remained on their fingers

[0316] ○: More than 7 people felt that it was smooth when spread, but the bacterial flora improving agent remained on their fingers

[0317] △: More than 7 people felt that it was not smooth when spreading, but there was no bacterial flora improving agent left on their fingers

[0318] ×: More than 7 people felt that it was not smooth when spreading and that the bacterial flora improving agent remained on their fingers

[0319] [Table 1-1]

[0320]

[0321]

[0322]

[0323] [Table 1-2]

[0324]

[0325]

[0326] [Table 1-3]

[0327]

[0328]

[0329]

[0330] [Table 1-4]

[0331]

[0332]

[0333]

[0334] [Table 1-5]

[0335]

[0336]

[0337] [Table 1-6]

[0338]

[0339]

[0340]

[0341] [Table 2]

[0342]

[0343] [Table 3]

[0344]

[0345] As shown in Tables 1-1 to 1-6, in Examples 1 to 44 comprising substance (X) and substance (Y), compared with Comparative Examples 1 to 16, the proliferation of pathogenic bacteria is selectively inhibited, and the proliferation of non-pathogenic bacteria is not inhibited, and an ideal bacterial flora balance can be achieved, so the bacterial flora improvement effect can be confirmed.

[0346] In addition, in Comparative Examples 15 and 16 using common antibacterial agents (benzalkonium chloride or cetylpyridinium chloride), the proliferation of not only pathogenic bacteria but also non-pathogenic bacteria was inhibited. In contrast, in Examples 1 to 44, the proliferation of non-pathogenic bacteria was maintained, suggesting that a selective inhibitory effect was exerted on pathogenic bacteria.

[0347] In addition, the inhibitory effect on toxin (protease) production of pathogenic bacteria was also confirmed in Examples 1 to 44. In addition, compared with Comparative Examples 11 to 12 and 14 which still showed the inhibitory effect on protease production, the long-term sustainability of the flora improvement effect was confirmed.

[0348] Therefore, it can be seen that the flora improving agent of the present invention has the effect of inhibiting proliferation and toxin production in a pathogenic bacteria selective manner without affecting non-pathogenic bacteria, and this effect can be sustained for a long time. As long as the flora improving agent of the present invention is applied once to the affected part, it can exert the flora balance improvement effect for a long time, so it can be seen that it is particularly useful as a flora improving agent.

Claims

1. A flora improving agent for improving the flora of mucous membranes, skin and / or nails, comprising a substance (X) and a base (Y) containing a non-volatile component, wherein the substance (X) is at least one selected from the group consisting of a compound (X1) having two or more hydroxyl groups contained in an oxyacid group and a salt thereof, a compound (X2) having one hydroxyl group contained in an oxyacid group and a salt thereof, a heterocyclic compound (X3) having no oxyacid group and a salt thereof, and a ketone (X4) having no oxyacid group, wherein: The total mass ratio of the oxyacid groups, the hydroxyl groups not contained in the oxyacid groups, the carbonyl groups not contained in the oxyacid groups, the carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and the nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton of the compound (X1) is 45% by mass or more, based on the molecular weight of the compound (X1), The compound (X2) contains atoms having an unshared electron pair, excluding atoms contained in an oxo acid group, and atoms contained in an amino group that does not constitute an imidazole skeleton and an amino group that does not constitute a pyridine skeleton. The total mass ratio of the oxyacid groups, the hydroxyl groups not contained in the oxyacid groups, the carbonyl groups not contained in the oxyacid groups, the carbon atoms contained in the imidazole skeleton and the pyridine skeleton, and the nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton of the compound (X2) is 55% by mass or more, based on the molecular weight of the compound (X2), The heterocyclic compound (X3) has an imidazole skeleton or a pyridine skeleton, and a hydroxyl group and / or a carbonyl group, or has two or more skeletons selected from imidazole skeletons and pyridine skeletons, The ketone (X4) has a linear β-diketone structure, The molecular weight of substance (X) is 550 or less, The HLB value of the non-volatile component is 7 or more, The microflora improving agent meets the following conditions (i) to (ii): (i) the bacterial flora improving agent has a mixing consistency of 100 to 400 as measured in accordance with JIS K 2220; (ii) The bacterial flora improving agent has a viscosity at 37° C. of 1 Pa·s to 4,000 Pa·s as measured using a cone-plate rotational viscometer.

2. The microflora improving agent according to claim 1, wherein The pH of the liquid obtained by diluting the above-mentioned flora improving agent with water so as to have a concentration of 1% by weight is 6 to 8.

3. The bacterial flora improving agent according to claim 1 or 2, wherein Based on the weight of the bacterial flora improving agent, the weight ratio of the substance (X) is 0.01 wt % to 5 wt %.